Lunai Bioworks Inc.

Published in Nature Communications, a new study uncovers critical protein biomarkers that predict functional decline in Duchenne Muscular Dystrophy (DMD), opening doors to more personalized care and improved clinical trials.

Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price

Proprietary safety intelligence creates dual value: faster therapeutic development and biodefense.

Company remains committed to Europe with a streamlined, growth-focused approach.

Collaboration aims to apply Lunai Bioworks Inc. biomedical AI platform to accelerate countermeasure development for chemical agents like sarin and other biothreats

Strategic IP expansion protects federated learning technology driving pharma partnerships, biosecurity initiatives, and precision medicine growth

Landmark preclinical data validate Renovaro's platform representing a step forward in the fight against pancreatic and solid tumors